Prelude Therapeutics Stock Performance
| PRLD Stock | USD 1.39 0.04 2.96% |
Prelude Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The company holds a Beta of 0.87, which implies possible diversification benefits within a given portfolio. Prelude Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Prelude Therapeutics is expected to follow. Use Prelude Therapeutics jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to analyze future returns on Prelude Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Prelude Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain essential indicators, Prelude Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Disposition of 9375 shares by Huang Jane of Prelude Therapeutics subject to Rule 16b-3 | 10/03/2025 |
2 | Can Prelude Therapeutics Incorporated stock sustain free cash flow growth - 2025 Trading Recap AI Forecasted EntryExit Points - newser.com | 10/15/2025 |
3 | Is Prelude Therapeutics Incorporated stock supported by innovation pipeline - 2025 Top Decliners Reliable Entry Point Alerts - newser.com | 10/21/2025 |
4 | Will Prelude Therapeutics Incorporated stock deliver shareholder value - Analyst Upgrade Low Drawdown Trading Strategies - newser.com | 10/24/2025 |
5 | 3 Compelling Penny Stocks With Market Caps Under 600M | 10/27/2025 |
6 | Can Prelude Therapeutics Incorporated stock sustain free cash flow growth - July 2025 Movers Precise Swing Trade Entry Alerts - newser.com | 10/31/2025 |
7 | Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting | 11/03/2025 |
8 | Dow Dips Over 400 Points Pfizer Earnings Top Estimates | 11/04/2025 |
9 | Prelude Therapeutics Evaluating Valuation After Incyte Deal and Strategic Pipeline Shift - simplywall.st | 11/07/2025 |
10 | Is Prelude Therapeutics Incorporated stock ready for a breakout - Trade Analysis Summary Short-Term Trading Alerts - newser.com | 11/10/2025 |
| Begin Period Cash Flow | 29.3 M | |
| Total Cashflows From Investing Activities | 90.2 M |
Prelude Therapeutics Relative Risk vs. Return Landscape
If you would invest 95.00 in Prelude Therapeutics on August 14, 2025 and sell it today you would earn a total of 40.00 from holding Prelude Therapeutics or generate 42.11% return on investment over 90 days. Prelude Therapeutics is currently generating 2.2099% in daily expected returns and assumes 21.8024% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Prelude, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Prelude Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prelude Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Prelude Therapeutics, and traders can use it to determine the average amount a Prelude Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1014
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | PRLD | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 21.8 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.21 actual daily | 44 56% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Prelude Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prelude Therapeutics by adding it to a well-diversified portfolio.
Prelude Therapeutics Fundamentals Growth
Prelude Stock prices reflect investors' perceptions of the future prospects and financial health of Prelude Therapeutics, and Prelude Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prelude Stock performance.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (19.29) % | ||||
| Current Valuation | 16.02 M | ||||
| Shares Outstanding | 43.75 M | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 10.92 X | ||||
| Revenue | 7 M | ||||
| Gross Profit | 7 M | ||||
| EBITDA | (137.94 M) | ||||
| Net Income | (127.17 M) | ||||
| Cash And Equivalents | 246.3 M | ||||
| Cash Per Share | 5.19 X | ||||
| Total Debt | 18.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.73 X | ||||
| Book Value Per Share | 1.00 X | ||||
| Cash Flow From Operations | (102.89 M) | ||||
| Earnings Per Share | (1.64) X | ||||
| Market Capitalization | 76.41 M | ||||
| Total Asset | 175.51 M | ||||
| Retained Earnings | (583.56 M) | ||||
| Working Capital | 110.25 M | ||||
About Prelude Therapeutics Performance
By analyzing Prelude Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Prelude Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prelude Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prelude Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.72) | (0.76) | |
| Return On Capital Employed | (0.93) | (0.98) | |
| Return On Assets | (0.72) | (0.76) | |
| Return On Equity | (0.97) | (0.92) |
Things to note about Prelude Therapeutics performance evaluation
Checking the ongoing alerts about Prelude Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prelude Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Prelude Therapeutics is way too risky over 90 days horizon | |
| Prelude Therapeutics may become a speculative penny stock | |
| Prelude Therapeutics appears to be risky and price may revert if volatility continues | |
| Prelude Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 7 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Is Prelude Therapeutics Incorporated stock ready for a breakout - Trade Analysis Summary Short-Term Trading Alerts - newser.com |
- Analyzing Prelude Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prelude Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Prelude Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Prelude Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prelude Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Prelude Therapeutics' stock. These opinions can provide insight into Prelude Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |